GlassScriptPhysician profile
Thomas Ferrise
NPI 1396364394
$18,108.01
in general payments reported to CMS, 2019-2025
26 companies · $1,872 in 2025
The $1,872 reported for 2025 was more than what 82% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,609 · 2022: $8,957 · 2023: $2,321 · 2024: $3,348 · 2025: $1,872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,814 · Travel and Lodging: $2,728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,813.93 |
| Travel and Lodging | $2,727.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $5,591.06 | 2022-2025 | Prostep, Augment Injectable, Prostep Mica |
| Reel Surgical, INC. | $4,835.49 | 2021-2022 | |
| Paragon 28, INC. | $1,751.98 | 2023-2025 | Ankle Fracture, Trauma, Apex 3d |
| Arthrex, INC. | $1,711.07 | 2022 | |
| Trimed, INC. | $967.81 | 2025 | |
| Smith+Nephew, INC. | $648.26 | 2022-2023 | Pico 14, Renasys Go V2 Home, Collagenase Santyl |
| Sanara Medtech INC. | $608.68 | 2023-2024 | Celleraterx |
| Linvatec Corporation | $534.62 | 2023-2024 | Biobrace 23mm, Allograft Tissue |
| Integra Lifesciences Corporation | $330.78 | 2021-2022 | |
| Exactech, INC. | $157.67 | 2023 | |
| Foundation Fusion Solutions, LLC | $157.20 | 2025 | |
| Horizon Therapeutics Plc | $125.00 | 2021 | |
| Treace Medical Concepts, INC. | $89.67 | 2022 | |
| Orthofix Medical, INC. | $89.41 | 2023-2024 | Physio-Stim |
| Mimedx Group, INC. | $86.73 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medshape, INC. | $73.86 | 2023 | Dynanail |
| Amgen INC. | $58.90 | 2024-2025 | Krystexxa |
| Depuy Synthes Sales INC. | $58.84 | 2025 | Na, Minibunion |
| Evolution Surgical, INC | $55.71 | 2023 | |
| Kerecis Limited | $49.81 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Musculoskeletal Transplant Foundation INC. | $26.76 | 2024 | |
| Kyowa Kirin, INC. | $25.48 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $20.92 | 2025 | Caldolor |
| Averitas Pharma INC. | $19.49 | 2023 | Qutenza |
| Spr Therapeutics, INC | $18.94 | 2025 | Sprint Pns System |
| Davol INC. | $13.87 | 2025 | Surgiphor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ferrise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.